Regressing cutaneous malignant melanoma and vitiligo‐like depigmentation

Arpaia, Nicola; Cassano, Nicoletta; Veña, Gino Antonio

doi:10.1111/j.1365-4632.2004.02468.x

Cited by 30 publications

(21 citation statements)

References 45 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is the first illustration of a delayed post-therapeutic regression of MM. It appears similar to the spontaneous regression reported for melanoma [5], and marginal zone B-cell lymphoma [6] in approximately one out of every 140 000 patients with cancer [7]. In our patient, a slow response could be expected because of the long remission after the first line therapy (seven years).…”

Section: Case Report and Discussionsupporting

confidence: 89%

Delayed complete remission in a patient with multiple myeloma

Ria

Vacca

Mangialardi

et al. 2008

Eur J Clin Investigation

View full text Add to dashboard Cite

We report a strikingly positive, late response to bortezomib in conjunction with pegylated liposomal doxorubicin in a 79-year old woman with multiple myeloma (MM). The patient obtained a partial remission after eight courses of therapy and a complete remission about 10 months after the end of therapy. This delayed complete remission may be similar to the spontaneous regression reported for other malignancies such as melanoma or lymphoma. We postulate that the immune response and a persistent anti-angiogenic effect of bortezomib could well explain the delayed complete remission in our patient.

show abstract

Section: Case Report and Discussionsupporting

confidence: 89%

Delayed complete remission in a patient with multiple myeloma

Ria

Vacca

Mangialardi

et al. 2008

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Furthermore, preclinical and clinical responses have been shown to correlate with the occurrence of vitiligo, which involves an autoimmune response against normal melanocytes. 41 Indeed, the deliberate establishment of an autoimmune response against normal melanocytes has been proposed as a potential approach for promoting antimelanoma immunity. 42,43 Therefore, therapies that provoke immune activation in addition to direct tumour-specific cytotoxicity represent rational approaches to the treatment of MMM.…”

Section: Discussionmentioning

confidence: 99%

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

et al. 2008

View full text Add to dashboard Cite

Reovirus is a promising unmodified double-stranded RNA (dsRNA) anti-cancer oncolytic virus, which is thought to specifically target cells with activated Ras. Although reovirus has been tested in a wide range of preclinical models and has entered early clinical trials, it has not previously been tested for the treatment of human melanoma. Here, we show that reovirus effectively kills and replicates in both human melanoma cell lines and freshly resected tumour; intratumoural injection also causes regression of melanoma in a xenograft in vivo model. Reovirus-induced melanoma death is blocked by caspase inhibition and is dependent on constituents of the Ras/RalGEF/p38 pathway. Reovirus melanoma killing is more potent than, and distinct from, chemotherapy or radiotherapy-induced cell death; a range of inflammatory cytokines and chemokines are released by infected tumour cells, while IL-10 secretion is abrogated. Furthermore, the inflammatory response generated by reovirus-infected tumour cells causes bystander toxicity against reovirus-resistant tumour cells and activates human myeloid dendritic cells (DC) in vitro. Hence, reovirus is suitable for clinical testing in melanoma, and may provide a useful danger signal to reverse the immunologically suppressive environment characteristic of this tumour.

show abstract

“…These features are strongly associated with MM, indicating the need for histopathological confirmation. 4 A vitiligo-like halo around a PSL is often interpreted as a reassuring clinical feature. A halo around an MM may therefore lead to errors in diagnosis and incorrect follow-up.…”

mentioning

confidence: 99%